Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer

por Bottini, A, Berruti, A, Brizzi, M P, Bersiga, A, Generali, D, Allevi, G, Aguggini, S, Bolsi, G, Bonardi, S, Bertoli, G, Alquati, P, Dogliotti, L
Publicado 2003

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

por Bottini, A, Berruti, A, Bersiga, A, Brizzi, M P, Bruzzi, P, Aguggini, S, Brunelli, A, Bolsi, G, Allevi, G, Generali, D, Betri, E, Bertoli, G, Alquati, P, Dogliotti, L
Publicado 2001

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

por Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A L, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A
Publicado 2008

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment

por Generali, D, Buffa, F M, Deb, S, Cummings, M, Reid, L E, Taylor, M, Andreis, D, Allevi, G, Ferrero, G, Byrne, D, Martinotti, M, Bottini, A, Harris, A L, Lakhani, S R, Fox, S B
Publicado 2014

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy

por Koukourakis, M I, Giatromanolaki, A, Bottini, A, Cappelletti, M R, Zanotti, L, Allevi, G, Strina, C, Ardine, M, Milani, M, Brugnoli, G, Martinotti, M, Ferrero, G, Bertoni, R, Ferrozzi, F, Harris, A L, Generali, D
Publicado 2014

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

por Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D
Publicado 2013

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

por Conte, P F, Donati, S, Gennari, A, Guarneri, V, Orlandini, C, Rondini, M, Roncella, M, Marini, L, Collecchi, P, Viacava, P, Naccarato, A G, Degli Esposti, R, Bonardi, S, Bottini, A, Saracchini, S, Tumolo, S, Gullo, G, Santoro, A, Crino, L
Publicado 2005

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

por Berruti, A, Bitossi, R, Gorzegno, G, Bottini, A, Generali, D, Milani, M, Katsaros, D, Rigault de la Longrais, I A, Bellino, R, Donadio, M, Ardine, M, Bertetto, O, Danese, S, Sarobba, M G, Farris, A, Lorusso, V, Dogliotti, L
Publicado 2005

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature

por Boutros, A., Bottini, A., Rossi, G., Tanda, E.T., Spagnolo, F., Barletta, G., Croce, E., Fava, P., Parisi, A., De Rosa, F., Palla, M., Marconcini, R., Ferrari, M., Grandis, M., Spallarossa, P., Sarocchi, M., Arboscello, E., Del Mastro, L., Lambertini, M., Pronzato, P., Genova, C.
Publicado 2023

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

por Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D
Publicado 2015